Oncopeptides AB (STU:OND)
€ 0.129 -0.0016 (-1.23%) Market Cap: 28.92 Mil Enterprise Value: 17.40 Mil PE Ratio: 0 PB Ratio: 2.40 GF Score: 29/100

Q3 2024 Oncopeptides AB Earnings Call Transcript

Nov 07, 2024 / 09:00AM GMT
Release Date Price: €0.1738 (-0.91%)
Sofia Heigis
Oncopeptides AB - Chief Executive Officer, Managing Director - Tyskland

Hi everyone and welcome to this presentation of our report for the third quarter of 2024. This is our standard disclaimer. As always, I have Henrik Bergentofts with me who will give a financial update before that I will go over some key points for the third quarter.

I will then come back with an update of our European commercialization and provide a deep dive on our three key markets in Europe, Germany including Austria, Spain and Italy. Starting off with some key highlights. The revenue in Q3 was SEK8.5 million. A slight increase versus Q2 and without a milestone payment from SCBIO for South Korea.

European sales in third quarter are slightly lower than in the second quarter, which in turn showed a 60% increase over Q1. We do see a strong start in Spain where we during this quarter have broad and regional access. Year-to-date we have unlocked 80% of the regions which we are pleased with. The speed we are moving with is due to a high unmet need for CapEx and a function of the positive clinical

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot